Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
National Journal of Andrology ; (12): 406-411, 2017.
Article in Chinese | WPRIM | ID: wpr-812752

ABSTRACT

Objective@#To investigate the expressions of extracellular signal-regulated kinase (ERK) and p-ERK in benign and malignant prostate tissues, and whether it can be used as a marker for the prognosis of advanced prostate cancer (PCa).@*METHODS@#Using immunohistochemical Envision, we detected the expressions of ERK1/2 and p-ERK1/2 in 20 cases of benign prostatic hyperplasia (BPH) and 40 cases of advanced PCa and analyzed their correlation with PCa metastasis, Gleason score, PSA level, and prognosis.@*RESULTS@#The expression of ERK1/2 was remarkably higher in the advanced PCa than in the BPH cases (82.5% vs 55%, P5 yr, and survival ≤ 5 yr groups were 61.9%, 89.5%, 57.9%, and 90.5%, respectively, with statistically significant differences among these groups (P<0.05).@*CONCLUSIONS@#ERK1/2 and p-ERK1/2 proteins are highly expressed in advanced PCa and p-ERK1/2 is associated with the metastasis and prognosis of advanced PCa.


Subject(s)
Humans , Male , Biomarkers, Tumor , Metabolism , Extracellular Signal-Regulated MAP Kinases , Metabolism , Mitogen-Activated Protein Kinase 1 , Metabolism , Mitogen-Activated Protein Kinase 3 , Metabolism , Neoplasm Grading , Neoplasm Metastasis , Prognosis , Prostate , Prostate-Specific Antigen , Metabolism , Prostatic Hyperplasia , Pathology , Prostatic Neoplasms , Mortality , Pathology
2.
National Journal of Andrology ; (12): 152-155, 2014.
Article in Chinese | WPRIM | ID: wpr-267960

ABSTRACT

<p><b>OBJECTIVE</b>To explore the mechanism of erectile dysfunction (ED) with testosterone deficiency and discuss the feasibility of long-term testosterone replacement therapy (TRT) by observing a case of ED with testosterone deficiency treated by TRT for 65 months.</p><p><b>METHODS</b>We treated an ED patient with testosterone deficiency by TST for 65 months, and evaluated the therapeutic effects by analyzing his IIEF-5 score, dynamic changes in testosterone, PSA, hemoglobin and red blood cell count, and adverse events.</p><p><b>RESULTS</b>The patient was a 46-year-old man, with an IIEF-5 score of 7, baseline serum total testosterone (TT) of 2.79 ng/ml, and no response to phosphodiesterases-5 inhibitors (PDE5i). He was diagnosed with late-onset hypogonadism (LOH) and treated by TRT: testosterone undecanoate at 80 mg bid po for the first 2 weeks and then at 40 mg bid po. Two months after medication, the TT level was increased to normal (3.45 ng/ml), and physical fitness and anxiety symptoms were markedly improved, with no significant improvement in sexual function. Then we administered PDE5i on demand in addition, which elevated his IIEF-5 score to > 21. The combined medication of TRT and on-demand PDE5i lasted for 45 months followed by TRT alone for another 18 months. The patient was restored to normal penile erection and sexual satisfaction, with the IIEF-5 score remaining at > 21. Regular follow-up revealed no significant abnormalities in the testosterone level, PSA, and routine blood tests.</p><p><b>CONCLUSION</b>TRT enhances the effect of PDE5i in the treatment of androgen deficiency-induced ED, and long-term TRT is safe and effective for androgen deficiency.</p>


Subject(s)
Humans , Male , Middle Aged , Androgens , Erectile Dysfunction , Drug Therapy , Hormone Replacement Therapy , Testosterone , Therapeutic Uses , Treatment Outcome
3.
National Journal of Andrology ; (12): 449-451, 2009.
Article in Chinese | WPRIM | ID: wpr-292353

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the effect and safety of transurethral prostatectomy with the bipolar plasmakinetic technique (PKRP) in the treatment of benign prostate hyperplasia (BPH).</p><p><b>METHODS</b>A total of 712 BPH patients underwent transurethral prostatectomy with the bipolar plasmakinetic technique. The patients averaged 70.6 years of age and 52 g (range 35-102 g) in estimated prostate weight preoperatively. Comparative analyses were made on the maximum urine flow rate (Qmax), residual urine volume and scores on IPSS and QOL obtained pre- and post-operatively.</p><p><b>RESULTS</b>The operations lasted 20-120 minutes (mean 51 min), the resected tissues weighed 15-96 g (mean 46 g), and no transurethral resection syndrome (TURS) occurred. The catheters were removed 4 -5 days after surgery. The patients were followed up for 1 -52 months (mean 27.6 mo). Obvious reduction was observed in the average Qmax from 4.7 ml/s preoperatively to 19. 1 ml/s postoperatively, in the mean IPSS score from 26.6 to 5. 8, and in the mean QOL score from 5.4 to 1.7, all with significant differences (P < 0.01).</p><p><b>CONCLUSION</b>Transurethral prostatectomy with the bipolar plasmakinetic technique is a safe and effective means for the treatment of BPH.</p>


Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Prostatic Hyperplasia , General Surgery , Transurethral Resection of Prostate , Methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL